

# World Journal of *Diabetes*

*World J Diabetes* 2017 June 15; 8(6): 230-310



### FIELD OF VISION

- 230 Statins redux: A re-assessment of how statins lower plasma cholesterol  
*Raghow R*

### REVIEW

- 235 Diabetes mellitus and stroke: A clinical update  
*Tun NN, Arunagirinathan G, Munshi SK, Pappachan JM*
- 249 Diabetes-induced mechanophysiological changes in the small intestine and colon  
*Zhao M, Liao D, Zhao J*

### MINIREVIEWS

- 270 Effects of glucose-lowering agents on ischemic stroke  
*Avgerinos K, Tziomalos K*
- 278 Treatment of type 2 diabetes mellitus in the elderly  
*Yakaryılmaz FD, Öztürk ZA*

### ORIGINAL ARTICLE

#### Observational Study

- 286 Statin use and cognitive function in middle-aged adults with type 1 diabetes  
*Nunley KA, Orchard TJ, Ryan CM, Miller R, Costacou T, Rosano C*
- 297 Risk factors for low high-density lipoprotein among Asian Indians in the United States  
*Lucke-Wold B, Misra R, Patel TG*
- 304 Interleukin-18 polymorphism as an inflammatory index in metabolic syndrome: A preliminary study  
*Fatima SS, Jamil Z, Abidi SH, Nadeem D, Bashir Z, Ansari A*

**ABOUT COVER**

Editorial Board Member of *World Journal of Diabetes*, Gerald H Tomkin, FACP, FRCS (Ed), MD, Professor, Department of Clinical Medicine, Beacon Clinic, Dublin 18, Israel

**AIM AND SCOPE**

*World Journal of Diabetes* (*World J Diabetes, WJD*, online ISSN 1948-9358, DOI: 10.4239), is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

*WJD* covers topics concerning  $\alpha$ ,  $\beta$ ,  $\delta$  and PP cells of the pancreatic islet, the effect of insulin and insulinresistance, pancreatic islet transplantation, adipose cells and obesity.

We encourage authors to submit their manuscripts to *WJD*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

**INDEXING/ABSTRACTING**

*World Journal of Diabetes* is now indexed in Emerging Sources Citation Index (Web of Science), PubMed, PubMed Central, and Scopus.

**FLYLEAF**

I-VI Editorial Board

**EDITORS FOR THIS ISSUE**

**Responsible Assistant Editor:** *Xiang Li*  
**Responsible Electronic Editor:** *Huan-Liang Wu*  
**Proofing Editor-in-Chief:** *Lian-Sheng Ma*

**Responsible Science Editor:** *Fung-Fung Ji*  
**Proofing Editorial Office Director:** *Jin-Lei Wang*

**NAME OF JOURNAL**  
*World Journal of Diabetes*

**ISSN**  
 ISSN 1948-9358 (online)

**LAUNCH DATE**  
 June 15, 2010

**FREQUENCY**  
 Monthly

**EDITORS-IN-CHIEF**  
**Lu Qi, MD, PhD, Assistant Professor**, Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, United States

**Jingbo Zhao, PhD, Associate Professor**, Aalborg Hospital Science and Innovation Centre, Aalborg Hospital, Aarhus University Hospital, Aalborg 9000, Denmark

**EDITORIAL BOARD MEMBERS**  
 All editorial board members resources online at <http://www.wjnet.com/1948-9358/editorialboard.htm>

**EDITORIAL OFFICE**

Xiu-Xia Song, Director  
*World Journal of Diabetes*  
 Baishideng Publishing Group Inc  
 7901 Stoneridge Drive, Suite 501,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [editorialoffice@wjnet.com](mailto:editorialoffice@wjnet.com)  
 Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjnet.com>

**PUBLISHER**

Baishideng Publishing Group Inc  
 7901 Stoneridge Drive, Suite 501,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [bpgoffice@wjnet.com](mailto:bpgoffice@wjnet.com)  
 Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjnet.com>

**PUBLICATION DATE**  
 June 15, 2017

**COPYRIGHT**

© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

**INSTRUCTIONS TO AUTHORS**

<http://www.wjnet.com/bpg/gerinfo/204>

**ONLINE SUBMISSION**

<http://www.f6publishing.com>

## Treatment of type 2 diabetes mellitus in the elderly

Funda Datli Yakaryılmaz, Zeynel Abidin Öztürk

Funda Datli Yakaryılmaz, Zeynel Abidin Öztürk, Division of Geriatric Medicine, Department of Internal Medicine, Faculty of Medicine, Gaziantep University, 27100 Sahinbey, Gaziantep, Turkey

Author contributions: Both authors contributed to this paper.

Conflict-of-interest statement: None to declare.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Zeynel Abidin Öztürk, MD, Division of Geriatric Medicine, Department of Internal Medicine, Faculty of Medicine, Gaziantep University, Osmangazi Avenue, University Street, 27100 Sahinbey, Gaziantep, Turkey. [zabidinozturk@gantep.edu.tr](mailto:zabidinozturk@gantep.edu.tr)  
Telephone: +90-342-3416689  
Fax: +90-342-3606060

Received: March 3, 2017

Peer-review started: March 7, 2017

First decision: April 18, 2017

Revised: May 11, 2017

Accepted: May 18, 2017

Article in press: May 19, 2017

Published online: June 15, 2017

### Abstract

The prevalence of type 2 diabetes is expected to increase gradually with the prolongation of population aging and life expectancy. In addition to macrovascular and microvascular complications of elderly patients of diabetes mellitus, geriatric syndromes such as cognitive impairment, depression, urinary incontinence,

falling and polypharmacy are also accompanied by aging. Individual functional status in the elderly shows heterogeneity so that in these patients, there are many unanswered questions about the management of diabetes treatment. The goals of diabetes treatment in elderly patients include hyperglycemia and risk factors, as in younger patients. comorbid diseases and functional limitations of individuals should be taken into consideration when setting treatment targets. Thus, treatment should be individualized. In the treatment of diabetes in vulnerable elderly patients, hypoglycemia, hypotension, and drug interactions due to multiple drug use should be avoided. Since it also affects the ability to self-care in these patients, management of other concurrent medical conditions is also important.

**Key words:** Diabetes mellitus; Oral antidiabetic drugs; Insulin; Elderly

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Diabetes mellitus (DM) is one of the most common lifelong chronic diseases in the world and its ratio is increasing by aging population. Elderly patients with type 2 DM have an increased risk for coronary heart disease, stroke and vascular diseases. While determining the treatment target and treatment options in elderly individuals, the functional capacity of the individual, comorbid diseases and treatment compliance should be evaluated together.

Yakaryılmaz FD, Öztürk ZA. Treatment of type 2 diabetes mellitus in the elderly. *World J Diabetes* 2017; 8(6): 278-285 Available from: URL: <http://www.wjgnet.com/1948-9358/full/v8/i6/278.htm> DOI: <http://dx.doi.org/10.4239/wjd.v8.i6.278>

### INTRODUCTION

The prevalence of type 2 diabetes is expected to increase gradually with the prolongation of population

aging and life expectancy. In addition to macrovascular and microvascular complications of elderly patients of diabetes mellitus (DM), geriatric syndromes such as cognitive impairment, depression, urinary incontinence, falling, polypharmacy and sarcopenia are also accompanied by aging<sup>[1]</sup>. Sarcopenia is characterised by a progressive decline in skeletal muscle mass and that is the reason for low muscle strength and impaired physical performance<sup>[2]</sup>. Elderly (adults over age 65 years) individuals with type 2 DM have a great risk for sarcopenia and physical disability<sup>[3]</sup>. The mechanism responsible for loss of muscle in type 2 DM is uncertain. Changes in skeletal muscle protein turnover may be involved in such alterations in type 2 DM and it can play an essential role in this pathogenesis<sup>[4,5]</sup>. There is also a small amount of studies involving elderly diabetic patients, one of the major reasons for that is individual functional status in the elderly shows heterogeneity. The physiological changes that develop with aging make it more difficult than studies for the young age group. As a result, there are many unanswered questions about the management of diabetes treatment in elderly patients. The "patient-centered" treatment regime in the geriatric age group is gaining importance for this reason.

### **Incidence**

Type 2 diabetes is a common health care problem on modern world and it is increasing day by day with the prolongation of life span. In a study conducted in the United States, it was found that the prevalence of type 2 diabetes increased from 16% to 23% between 1995 and 2004<sup>[6]</sup>. According to the current data, in the United States, among adults over 65 years of age 22% to 33% of them are diagnosed with diabetes. It is predictable that the incidence of diabetes could double in the next 20 years. According to another projection; It is estimated that this increase will be about 4.5 times between 2005 and 2050 in individuals aged 65 and over<sup>[1]</sup>.

### **Diabetic characteristics in the elderly population**

Glucose intolerance increases progressively by aging and the characteristic feature of diabetes in elderly patients is especially postprandial hyperglycemia. Decrease in beta-cell-compensating capacity with advancing age, leads to insulin resistance and it appears as a postprandial hyperglycaemia in the elderly<sup>[7]</sup>. Therefore, the prevalence varies according to the tests used during diagnosis on elderly patients. One third of the individuals who are tested with A1C or fasting plasma glucose (FPG) are cannot get a diagnosis<sup>[8]</sup>.

The incidence of DM increases with aging. As a result, adults may be diagnosed incidentally after the age of 65, or may have had a diabetes diagnosis in middle age or earlier onset. Having different demographic and clinical characteristics of these two groups may cause confusion caused by the setting of the general treatment recommendations. Age-related DM is characterized by

lower A1C and the use of less insulin, with frequent occurrence in non-Hispanic whites. In comparison adults with diabetes diagnosed in middle age, the retinopathy story is more prominent in late-onset diabetic cases, and interestingly there is no difference in prevalence of cardiovascular disease (CVD) or peripheral neuropathy according to age at onset<sup>[9]</sup>. In diabetic adults increased development risk of lower extremity amputation, myocardial infarction (MI), impaired vision and end-stage renal disease. Patients over 75 years of age have a higher risk of developing multiple complications than the age group of 65-74<sup>[10]</sup>.

Older adults are at higher risk for developing type 2 diabetes because of the combined effects of increased insulin resistance and pancreatic islet dysfunction.

### **Economic burden**

The burden of treatment of older diabetic patients on country economy is quite high. According to the analysis made in the United States in 2010; More than 14 million patients whose age 65 and over are hospitalized annually and approximately one-third of them are diabetic<sup>[11]</sup>. Again according to United States data, about \$245 million is spent yearly on diabetes patients, of which \$176 million is direct medical costs, while \$69 million is the loss of production and mortality<sup>[12]</sup>. In addition, 59% portion of the annual treatment costs have been made for the elderly diabetic individuals. Most of the expenditures are caused by hospital admissions, home care and prescribed drugs. These extreme expenditures vary from about \$23900 to \$40900 per person, depending on gender and age<sup>[13]</sup>.

## **TREATMENT TARGETS**

The goals of diabetes treatment in elderly patients include hyperglycemia and risk factors, as in younger patients. However, the elderly patient group has a heterogeneous structure, some of them are self-caring independently, while the others need care in a nursing home. For this reason, comorbid diseases and functional limitations of individuals should be taken into consideration when setting treatment targets. Thus, treatment should be individualized.

There is limited number of studies investigating the effect of glucose-lowering therapy on cardiovascular complications and mortality. For the reason that the elderly diabetic patient population is not included in clinical trials, we do not have sufficient data on glucose control.

In the United Kingdom Prospective Diabetes Study (UKPDS), in which the effect of glycemic control on microvascular complications is examined, new diagnoses of middle-aged diabetic patients were taken and > 65 years of age were excluded from the study<sup>[14]</sup>. At the end of the study, there was a statistically significant decrease in both mortality and cardiovascular events in the group ensured early glycemic control. Also observed that microvascular beneficial effects continue after the

study.

After the UKPDS results were published, three important randomized controlled trials (ACCORD trial, Action in Diabetes and Vascular Disease: Preterax and Diamicon MR Controlled Evaluation (ADVANCE) trial, and Veterans Affairs Diabetes Trial (VADT) are planned. These studies are designed to examine the effect of glycemic control on CVD events in middle-aged and older patients with type 2 diabetes. The ACCORD trial was terminated approximately 3 years after due to deaths on the strict glycemic control group<sup>[15]</sup>. MI, stroke and cardiovascular death were not significantly reduced in primary combined outcomes. In subgroup analyzes, hypoglycemia and other side effects were more commonly detected in elderly participants. In the ADVANCE trial, there was no increased risk of mortality in the strict glucose control group after 5 years of follow-up. When study data were evaluated, there was no statistically significant decrease in cardiovascular risks in the group receiving intensive treatment, however, a significant decrease in the incidence of nephropathy was found<sup>[16]</sup>. In the VADT trial, there was no statistically significant effect on major cardiovascular events or mortality in the intensive glucose control group after 5 years of follow-up, as well as there wasn't any reversible effect on albuminuria progression. In the intensive group, beneficial effects on mortality were observed in 15 year follow-ups, but higher mortality was found in this group over 20 years<sup>[17]</sup>.

These studies are important in assessing the benefits and risks of strict glycemic control in elderly patients. For this reason, when glycemic control targets are determined, treatment should be individualized considering the life expectancy as well as the chronological age of the patient.

In the treatment of diabetes in vulnerable elderly patients, hypoglycemia, hypotension, and drug interactions due to multiple drug use should be avoided. Since it also affects the ability to self-care in these patients, management of other concurrent medical conditions is also important.

### **Glycemic targets**

In elderly patients receiving medication, there are few data that address the most appropriate glycemic targets. The goals to be determined in the management of glycemic control and risk factors should be based on both the general health status and the predicted life span of the individual. A proper target for A1C in elderly patients with a life expectancy of more than 10 years may vary according to the above factors, the risks of patient-specific hypoglycemia and compliance with treatment regimens<sup>[18]</sup>.

Despite the lack of long-term clinical trials with elderly individuals, patients with life expectancy more than 10 years and drug treated the A1C target should be < 7.5% (58.5 mmol/mol).

Drug treated elderly adults with medically-functional comorbidities and have less than 10 years of life

expectancy should have a slightly higher glycemic target [A1C ≤ 8.0, fasting and pre-prandial glucose should be between 160 and 170 mg/dL (8.9 to 9.4 mmol/L)].

Individualized targets for older adults may be even higher (A1C < 8.5%). The aim of the treatment is to protect the quality of life, prevent hypoglycemia and related complications. Eight point five percent for A1C value and 200 mg/dL for average glucose (11.1 mmol/L) should be targeted.

These targets are consistent with the American Geriatrics Association, the American Diabetes Association, the International Diabetes Federation and the European Diabetes Working Group.

In addition, when A1C levels are assessed in elderly patients, accompanying diseases or metabolic conditions should be considered. These include anemia, diseases affecting the erythrocyte life, chronic kidney disease, chronic liver disease, recent blood transfusion or erythropoietin infusion, acute infections and hospitalization. Initial therapy in elderly patients, the same as in younger patients; regulation of nutrition, physical activity, improvement on metabolic control and prevention from complications.

### **Lifestyle changes**

Counseling should be provided on all elderly diabetic patient lifestyle changes (exercise, diet, behavioral changes, and weight loss in patients who need it). In elderly diabetic group response to the lifestyle changes (low fat diet and 150 min/wk exercise) were found to be higher than the young diabetic age group according to the diabetes protection program (DPP)<sup>[19]</sup>.

**Physical activity:** Elderly diabetic patients should be guided to activities according to their functional capacities. Prior to physical activity, high-risk, symptomatic individuals with coronary artery disease should be evaluated with electrocardiograms and/or cardiac tests. Functionally independent individuals are offered a moderate aerobic activity of at least 5 d for 30 min each week. Except this, patients with high risk of falling should be directed to physiotherapists for balance and muscle strengthening exercises before workout.

**Medical nutrition therapy:** All elderly diabetic patients should be given medical nutrition education and treatment should be adjusted to their individual needs. When preparing the eating plan, age-related person-specific differences (deterioration in taste, additional illnesses, dietary restrictions, impaired gastrointestinal function, reduced ability to shop, and reduced food preparation capacity) must be considered.

### **Medical therapy**

In elderly diabetic patients, lifestyle changes is recommended with metformin for treatment, primarily because of the risk of hypoglycemia, unless there is a contraindication (renal failure and unstable/acute heart failure)<sup>[20]</sup>. However, patients with comorbid disease,

multiple drug use, or HbA1c levels close to target levels should be monitored for 3-6 mo with lifestyle changes before initiation of metformin therapy.

At the time of diagnosis patients whose HbA1c level was > 9% (74.9 mmol/mol), FPG level was > 250 mg/dL (13.9 mmol/L), randomly observed glucose value > 300 mg/dL (16.7 mmol /L) or who have ketonuria insulin should be selected as initial therapy.

There is a small amount of research on the use of medication in elderly patients. All hypoglycemic drugs and insulins can be safely used in elderly patients, with some restrictions. In general, those with low risk of hypoglycemia should be preferred as oral or injected agents.

Pharmacological treatment should be regulated according to the person's abilities and comorbidities. Elderly patients should be treated with the principle of "start low and go slow". Oral antidiabetic drugs and insulin are used in the treatment of diabetes in the elderly.

---

## INSULIN SENSITIZER DRUGS

---

### **Metformin**

Metformin decreases hepatic glucose production by inhibiting gluconeogenesis in the liver. In many elderly patients, metformin is chosen as the initial treatment. Low cost, positive effects on CVDs, low risk of hypoglycemia the anti-aging effects makes metformin an attractive choice for elderly patients<sup>[21]</sup>. The most important restricting factor of metformin treatment is glomerular filtration rate (GFR) and treatment can be started if GFR of the patient is > 30 mL/min. It is recommended to use a full dose in patients with GFR > 60 mL/min and a half dose (1000 mg/d) in patients with GFR 30-60 mL/min. Two other factors that limit metformin treatment in elderly patients are weight loss and gastrointestinal side effects. However, the treatment may be started at 500 mg/d and the gastrointestinal side effects may be minimized by slowly increasing the dose within weeks.

Elderly patients should also be used metformin cautiously as it may cause renal dysfunction or lactic acidosis. Patients using metformin should be warned for stopping medication if the use of iodine-containing contrast media is needed for any reason. In addition, evaluation of renal function tests every 3 to 6 mo is necessary.

### **Thiazolidinediones**

Thiazolidinediones are peroxisome proliferator-activated receptor- $\gamma$  (PPAR- $\gamma$ ) agonist drugs and these drugs regulate the transcription of genes that respond with PPAR activation<sup>[22]</sup>. These drugs are effective in increasing insulin sensitivity in peripheral tissues, primarily skeletal muscles. It is the group of drugs that can be preferred in the elderly who are not using the insulin treatment and that the sulfonylurea treatment

is contraindicated. This drug group being able to be preferred in patients with impaired renal function, as well as low risk of hypoglycemia and has the greatest advantage to be well tolerated in elderly patients. Peripheral edema may develop in 4%-5% of patients during treatment, and is contraindicated in patients with class III-IV congestive heart disease<sup>[23]</sup>. In addition to these, the most important disadvantages are: It can exacerbate ophthalmopathy, increase the risk of bone fracture, increase weight in combination with insulin therapy, cardiovascular events (fatal and nonfatal MI) and increase in bladder cancer. Patients with active bladder cancer or history, defining macroscopic hematuria or having complaints of hematuria, dysuria, pollakuria, waist and back pain during thiazolidinedione usage should be screened for bladder cancer before the onset of treatment<sup>[24]</sup>. Because of the disadvantages of them (congestive heart failure, risk for falls or fractures), their use is not recommended on elderly patients, however for the selected patients dosage should be started at the lowest dose and the duration of treatment should be kept as short as possible<sup>[25]</sup>.

---

## INSULIN RELEASING (SECRETAGOGUE) DRUGS

---

### **Sulfonylureas**

Short-acting sulfonylureas (*e.g.*, glipizide) are recommended as initial therapy in patients with metformin therapy contraindicated or unable to tolerate it. Side effects such as hypoglycemia and weight gain should be considered in addition to glucose lowering effects, easy availability and low cost in the selection of sulfonylureas (SU). Glipizide, glyburide (glibenclamide), gliclazide and glimepiride are 2<sup>nd</sup> generation SUs and are more potent than 1<sup>st</sup> generation SU and have less side effects. Glyburide (glibenclamide) and glimepiride have a long half-life and are used in a single daily dose and reduce fasting glucose by inhibiting night hepatic glucose output and cause elevated risk of hypoglycemia<sup>[26]</sup>. The risk of hypoglycemia is increased especially in patients with renal insufficiency, elderly patients, multiple drug users, patients with dementia, heart failure and long-term diabetes<sup>[27]</sup>.

In elderly patients, sulfonylurea-related hypoglycemia is variable. In general, from diabetic patients in hospital, hypoglycemia was more common in patients aged > 75 years, compared to groups aged 65-74 years. Admission to the hospital with the cause of severe hypoglycemia in the elderly is associated with greater health problems than admission with hyperglycemia, which suggests to have opportunities to improve health through rational drug selection in the elderly with diabetes<sup>[28]</sup>. Short-acting ones such as glipizide should be preferred if the SU treatment is planned to be given in the elderly. The initial regimen of glipizide 2.5 mg should be regulated as half an hour before breakfast, and if sufficient glycemic control

cannot be achieved within 2-4 wk, the dosage should be increased to 5-10 mg.

### **Meglitinides**

Similar to sulphonylureas, act on pancreatic beta cells to increase the 1<sup>st</sup> phase of insulin secretion through ATP-dependent potassium channels through different receptors. The blood glucose lowering effect with fast onset and a short duration<sup>[29]</sup>. Especially the effects on postprandial hyperglycaemia are distinctive, so they are used just before meals. Use of just before each meal can cause discontinuation in the treatment of older adults with cognitive pathology<sup>[30]</sup>. The most important side effects, though not as obvious as SUs, are hypoglycemia and weight gain. The risk of hypoglycemia is more pronounced in older adults, especially those who skip meals. Repaglinide is metabolised from the liver, so it can be safely used in the elderly with renal insufficiency without need for dose adjustment. It is a good option as initial therapy in older patients with chronic renal failure who cannot tolerate metformin and SU treatment<sup>[31]</sup>. Also the repaglinidin's A1C lowering effect is higher than nateglinide.

## **ALPHA GLUCOSIDASE INHIBITORS**

They function by inhibiting carbohydrate absorption by inhibiting the enzyme alpha-glucosidase in the small intestine. The drugs in this group are acarbose, miglitol and voglibose. It is advised to take it before every meal but it can be used at the time of meal with postprandial hyperglycemia (PPH) only because it affects PPH. The most important side effects are swelling, indigestion, diarrhea, reversible increase in liver enzymes and rarely iron deficiency anemia. Contraindications include inflammatory bowel disease, chronic ulceration, malabsorption, partial bowel obstruction and cirrhosis. In addition, treatment should be discontinued in patients with an eGFR of 25 mL/min<sup>[32]</sup>.

## **INCRETIN BASED MEDICATIONS**

### **Dipeptidyl peptidase-4 inhibitors**

Dipeptidyl peptidase-4 inhibitors (DPP-4I) is a member of a large family of enzymes responsible for the destruction of many GIS hormones, neuropeptides, chemokines and cytokines. In response to food-borne carbohydrates, they are secreted from small intestine's K and L cells. They increase pancreatic insulin secretion, slow down gastric emptying, and suppress the increased postprandial glucagon secretion<sup>[33]</sup>. DPP-4 inhibitors are an attractive treatment option for elderly diabetic patients due to the single daily dose, lack of risk for hypoglycemia and neutral effect on weight. The most important side effects are headache, nasopharyngitis, upper respiratory tract infection and acute pancreatitis. Creatinine clearance should be calculated before treatment in each patient and dose should be reduced if < 50 mL/min. For sitagliptin if Egfr < 30 mL/min

for, it should preferably not be used and if the eGFR is between 30-50 mL/min, the dose should be reduced by 50%. If eGFR < 15 mL/min in vildagliptin, saxagliptin, and linagliptin, they should preferably not be used, but for Vildagliptin if eGFR between 30-60 mL/min or patient has dialyzed it can be used without dosage adjustment. For Alogliptin treatment, if the eGFR is 30-60 mL/min, the dose is reduced by 50%, whereas if the eGFR is < 30 mL/min, the dose is reduced by 75%.

In the study comparing glipizide and sitagliptin in elderly diabetic patients, A1C reduction was similar in both groups, but less hypoglycemic event was encountered in the alogliptin-receiving group<sup>[34]</sup>. In another study conducted by Scirica *et al*<sup>[35]</sup>, the group receiving saxagliptin treatment in elderly diabetic patients was found to have a higher rate of hospitalization with cardiac insufficiency. On the other hand; a systemetic review deduced that incretin-based treatment(agents) does not increase major adverse cardiovascular events<sup>[36]</sup>. The effects of the DPP-4 group drugs on the A1C lowering are insufficient. Therefore, monotherapy can be used in patients with A1C level close to the target value. They may also be added to metformin, SU and insulin therapy.

### **Incretinmimetics (glucagon like peptid-1 receptor agonists)**

Glucagon like peptid-1 receptor (GLP-1) agonist drugs also target postprandial hyperglycemia and their hypoglycemia risk is relatively low. However, nausea and weight loss are the most important side effects in vulnerable patients. Other negative features are that they are administered as injections, renal dose reduction and high treatment costs.

Studies have shown that at the end of the 24-wk follow-up period with liraglutide treatment, the decrease in fat mass and lipid profile, as well as the increase in glucose control and insulin sensitivity<sup>[37]</sup>. In another study about cardiovascular effects of liraglutide treatment, the incidence of non-fatal MI or nonfatal stroke due to cardiovascular causes was found to be lower in patients receiving liraglutide treatment compared to placebo<sup>[38]</sup>.

In another study, the rate of cardiovascular death, non-fatal MI, or non-fatal stroke was found to be significantly lower in type 2 diabetes patients with semaglutide treatment compared to those who received placebo. This result confirms the noninferiority of semaglutidine<sup>[39]</sup>.

### **Sodium glucose co-transporter 2 inhibitors = glucoretics**

Although there isn't any long-term efficacy and safety data available, they may be preferred as treatment options in cases in which sufficient glycemic control is not achieved with dual oral agents such as metformin and SU. Sodium glucose co-transporter 2 inhibitors (SGLT2-I) is secreted in the proximal tubules and reabsorbs about 90% of the glucose load undergoing filtration. The effect of lowering the plasma glucose level and A1C level is limited by the filtered glucose load and osmotic diuresis, and also insulin independent and can be used in any stage of DM2. A1C is reduced by

0.5%-1%. Even though long-term efficacy is unknown, but it has been found that within 2 to 6 mo, it causes about 2 kg of loss, 2-4 mmHg decline in systolic blood pressure, and 1-2 mmHg decline in diastolic KB. It also has the advantages of lowering the level of uric acid and decreased albuminuria and also low risk for hypoglycemia<sup>[40]</sup>. The most important side effects were increased genital-mycotic infections (11% in females, 4% in males) and an elevated volume gap due to increase in urinary tract infections and diuretic effects<sup>[41]</sup>.

When cardiovascular results of studies with these group drugs were evaluated, there was a significant decrease in the risk of cardiovascular events and cardiovascular caused mortality with Empagliflozin<sup>[42]</sup>. In the subgroup analysis of the same study, it was found that Empagliflozin has renoprotective effects and reduced the risk for development of renal complications<sup>[43]</sup>. The study of the concurrent use of DPP-4I and SGLT2-I treatment showed that monotherapy was more effective in patients treated with metformin, when a gliptin was added to gliflozin, it was determined that it had the effect of more glucose lowering than when a gliptin was added to gliptin. The opinion at the end of the meta-analysis is that SGLT2I and DPP-4I can be used as an initial combination or as a gradual approach and combining two pharmacological options is safe and does not induce hypoglycemia<sup>[44]</sup>. Furthermore, when the sum of the evidence for the use of dapagliflozin is assessed, it has not been shown that there is a causal relationship between dapagliflozin and bladder cancer, which was previously proposed<sup>[45]</sup>.

Should be used more carefully in elderly because for causing osmotic diuresis resulting dehydration, causing an increase in the frequency of genital and urinary system infections, weight loss, dose adjustment necessity in renal failure and lack of enough data on microvascular and cardiovascular outcomes.

## INSULIN THERAPY

In the elderly with poor glycemic control, HbA1c level > 9% (74.9 mmol/mol), FPG level > 250 mg/dL (13.9 mmol/L), randomized glucose value > 300 mg/dL or patients with ketonuria, insulin should be selected as initial therapy. When starting insulin therapy in elderly patients, it is important to have general health status, ability to make insulin, to measure blood sugar, to understand hypoglycemia and capacity to treat it. In the study of geriatric patients using basal insulin and OAD, treatment-related satisfaction surveys and post-12-wk follow-up in the insulin treatment group showed significant improvement in the geriatric depression scale (SOURCE). In another study, geriatric patients were divided into OAD treatment with basal insulin addition and elevated OAD dosage group, and 24-mo follow-up revealed a lower frequency of hypoglycemia in the basal insulin group (SOURCE). In a randomized controlled trial in long-term care patients, basal insulin was added to a group and OAD added to another group and

glycemic control and development of hypoglycemia were evaluated and no significant difference was detected. When the ready mixed insulins are evaluated, they are more effective for the control of postprandial glycaemia, but they are more useful for the patients who live in the nursing home, who eat regular meals.

New oral glucose-lowering agents are less likely to have all-cause mortality, CVD, and severe hypoglycemia when compared to insulin. Dapagliflozin has both decreased mortality due to all causes and reduced CVD risk, while DPP-4i has been found to be weaker in decrease of all cases due to mortality<sup>[46]</sup>.

Elderly patients have their own nutritional needs. Along with the increased age, the taste and odor sensations diminishes, as well as changes in the threshold of thirst. For this reason, the balance between pre-meal insulin and oral food intake should be well established in elderly patients. Insulin dose reduction should be done according to the amount of carbohydrates taken at meals, for example if half of the meal is consumed, insulin will be reduced by 50%, insulin will not be administered or 25% can be administered to patients who consume less than that or may skip meals due to a medical intervention. In addition, patients with enteral or parenteral nutrition should be monitored for glucose at 4-6 h intervals to avoid hypo-hyperglycaemia<sup>[47]</sup>.

## CONCLUSION

When starting OAD or insulin therapy in the elderly, treatment regimens containing as simple and few drugs as possible should be administered, and drug therapy should not be initiated unless it is necessary and if necessary must start with low dose and dose increase should be done slowly. All patients should be evaluated with liver and kidney function tests before onset of treatment.

## REFERENCES

- 1 **Kirkman MS**, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, Huang ES, Korytkowski MT, Munshi MN, Odegaard PS, Pratley RE, Swift CS. Diabetes in older adults: a consensus report. *J Am Geriatr Soc* 2012; **60**: 2342-2356 [PMID: 23106132 DOI: 10.1111/jgs.12035]
- 2 **Cruz-Jentoft AJ**, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing* 2010; **39**: 412-423 [PMID: 20392703 DOI: 10.1093/ageing/afq034]
- 3 **Kalyani RR**, Saudek CD, Brancati FL, Selvin E. Association of diabetes, comorbidities, and A1C with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999-2006. *Diabetes Care* 2010; **33**: 1055-1060 [PMID: 20185736 DOI: 10.2337/dc09-1597]
- 4 **Pereira S**, Marliss EB, Morais JA, Chevalier S, Gougeon R. Insulin resistance of protein metabolism in type 2 diabetes. *Diabetes* 2008; **57**: 56-63 [PMID: 17940118 DOI: 10.2337/db07-0887]
- 5 **Cuthbertson D**, Smith K, Babraj J, Leese G, Waddell T, Atherton P, Wackerhage H, Taylor PM, Rennie MJ. Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. *FASEB J*

- 2005; **19**: 422-424 [PMID: 15596483 DOI: 10.1096/fj.04-2640fje]
- 6 **Zhang X**, Decker FH, Luo H, Geiss LS, Pearson WS, Saaddine JB, Gregg EW, Albright A. Trends in the prevalence and comorbidities of diabetes mellitus in nursing home residents in the United States: 1995-2004. *J Am Geriatr Soc* 2010; **58**: 724-730 [PMID: 20398154 DOI: 10.1111/j.1532-5415.2010.02786.x]
  - 7 **Chang AM**, Halter JB. Aging and insulin secretion. *Am J Physiol Endocrinol Metab* 2003; **284**: E7-12 [PMID: 12485807 DOI: 10.1152/ajpendo.00366.2002]
  - 8 **Szoke E**, Shrayyef MZ, Messing S, Woerle HJ, van Haefen TW, Meyer C, Mitrakou A, Pimenta W, Gerich JE. Effect of aging on glucose homeostasis: accelerated deterioration of beta-cell function in individuals with impaired glucose tolerance. *Diabetes Care* 2008; **31**: 539-543 [PMID: 18083793 DOI: 10.2337/dc07-1443]
  - 9 **Selvin E**, Coresh J, Brancati FL. The burden and treatment of diabetes in elderly individuals in the u.s. *Diabetes Care* 2006; **29**: 2415-2419 [PMID: 17065677 DOI: 10.2337/dc06-1058]
  - 10 **Li Y**, Burrows NR, Gregg EW, Albright A, Geiss LS. Declining rates of hospitalization for nontraumatic lower-extremity amputation in the diabetic population aged 40 years or older: U.S., 1988-2008. *Diabetes Care* 2012; **35**: 273-277 [PMID: 22275440 DOI: 10.2337/dc11-1360]
  - 11 **Weir LM**, Pfunter A, Steiner C. Hospital Utilization among Oldest Adults, 2008. HCUP Statistical Brief #103. December 2010, Agency for Healthcare Research and Quality, Rockville, MD. Available from: URL: <http://www.hcup-us.ahrq.gov/reports/statbriefs/sb103.pdf>
  - 12 **American Diabetes Association**. Economic costs of diabetes in the U.S. in 2012. *Diabetes Care* 2013; **36**: 1033-1046 [PMID: 23468086 DOI: 10.2337/dc12-2625]
  - 13 **Zhuo X**, Zhang P, Barker L, Albright A, Thompson TJ, Gregg E. The lifetime cost of diabetes and its implications for diabetes prevention. *Diabetes Care* 2014; **37**: 2557-2564 [PMID: 25147254 DOI: 10.2337/dc13-2484]
  - 14 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998; **352**: 837-853 [PMID: 9742976 DOI: 10.1016/S0140-6736(98)07019-6]
  - 15 **Gerstein HC**, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008; **358**: 2545-2559 [PMID: 18539917 DOI: 10.1056/NEJMoa0802743]
  - 16 **Patel A**, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008; **358**: 2560-2572 [PMID: 18539916 DOI: 10.1056/NEJMoa0802987]
  - 17 **Duckworth W**, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009; **360**: 129-139 [PMID: 19092145 DOI: 10.1056/NEJMoa0808431]
  - 18 **Wei N**, Zheng H, Nathan DM. Empirically establishing blood glucose targets to achieve HbA1c goals. *Diabetes Care* 2014; **37**: 1048-1051 [PMID: 24513588 DOI: 10.2337/dc13-2173]
  - 19 National Diabetes Surveillance System: Diabetes Prevention Program. Available from: URL: <https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/diabetes-prevention-program-dpp/Pages/default.aspx>
  - 20 **Colagiuri S**, Cull CA, Holman RR. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61. *Diabetes Care* 2002; **25**: 1410-1417 [PMID: 12145243 DOI: 10.2337/diacare.25.8.1410]
  - 21 **Inzucchi SE**, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2012; **35**: 1364-1379 [PMID: 22517736 DOI: 10.2337/dc12-0413]
  - 22 **Yki-Järvinen H**. Thiazolidinediones. *N Engl J Med* 2004; **351**: 1106-1118 [PMID: 15356308 DOI: 10.1056/NEJMra041001]
  - 23 **Neumiller JJ**, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. *Am J Geriatr Pharmacother* 2009; **7**: 324-342 [PMID: 20129254 DOI: 10.1016/j.amjopharm.2009.12.002]
  - 24 **Kung J**, Henry RR. Thiazolidinedione safety. *Expert Opin Drug Saf* 2012; **11**: 565-579 [PMID: 22616948 DOI: 10.1517/14740338.2012.691963]
  - 25 **Marathe PH**, Gao HX, Close KL. American Diabetes Association Standards of Medical Care in Diabetes 2017. *J Diabetes* 2017; **9**: 320-324 [PMID: 28070960 DOI: 10.1111/1753-0407.12524]
  - 26 **Shorr RI**, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. *J Am Geriatr Soc* 1996; **44**: 751-755 [PMID: 8675920 DOI: 10.1111/j.1532-5415.1996.tb03729.x]
  - 27 **Holstein A**, Hammer C, Hahn M, Kulamadavil NS, Kovacs P. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. *Expert Opin Drug Saf* 2010; **9**: 675-681 [PMID: 20553106 DOI: 10.1517/14740338.2010.492777]
  - 28 **Lipska KJ**, Ross JS, Wang Y, Inzucchi SE, Minges K, Karter AJ, Huang ES, Desai MM, Gill TM, Krumholz HM. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. *JAMA Intern Med* 2014; **174**: 1116-1124 [PMID: 24838229 DOI: 10.1001/jamainternmed.2014.1824]
  - 29 **Fuhendorff J**, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. *Diabetes* 1998; **47**: 345-351 [PMID: 9519738 DOI: 10.2337/diabetes.47.3.345]
  - 30 **Yehuda AB**, Zinger A, Durso S. The older patient with diabetes: a practical approach. *Diabetes Metab Res Rev* 2014; **30**: 88-95 [PMID: 24123811 DOI: 10.1002/dmrr.2485]
  - 31 **Hasslacher C**. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. *Diabetes Care* 2003; **26**: 886-891 [PMID: 12610054 DOI: 10.2337/diacare.26.3.886]
  - 32 **Gentilcore D**, Vanis L, Wishart JM, Rayner CK, Horowitz M, Jones KL. The alpha ( $\alpha$ )-glucosidase inhibitor, acarbose, attenuates the blood pressure and splanchnic blood flow responses to intraduodenal sucrose in older adults. *J Gerontol A Biol Sci Med Sci* 2011; **66**: 917-924 [PMID: 21628676 DOI: 10.1093/gerona/66.9.917]
  - 33 **Koliaki C**, Doupis J. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. *Diabetes Ther* 2011; **2**: 101-121 [PMID: 22127804 DOI: 10.1007/s13300-011-0002-3]
  - 34 **Rosenstock J**, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. *Diabetes Obes Metab* 2013; **15**: 906-914 [PMID: 23531118 DOI: 10.1111/dom.12102]
  - 35 **Scirica BM**, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med* 2013; **369**: 1317-1326 [PMID: 23992601 DOI: 10.1056/NEJMoa1307684]
  - 36 **Rotz ME**, Ganetsky VS, Sen S, Thomas TF. Implications of incretin-based therapies on cardiovascular disease. *Int J Clin Pract* 2015; **69**: 531-549 [PMID: 25363540 DOI: 10.1111/ijcp.12572]
  - 37 **Rondanelli M**, Perna S, Astrone P, Grugnetti A, Solerte SB, Guido D. Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese

- patients with type 2 diabetes mellitus. *Patient Prefer Adherence* 2016; **10**: 407-413 [PMID: 27069358 DOI: 10.2147/PPA.S97383]
- 38 **Marso SP**, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med* 2016; **375**: 311-322 [PMID: 27295427 DOI: 10.1056/NEJMoa1603827]
- 39 **Marso SP**, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med* 2016; **375**: 1834-1844 [PMID: 27633186 DOI: 10.1056/NEJMoa1607141]
- 40 **Lajara R**. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. *Expert Opin Pharmacother* 2014; **15**: 2565-2585 [PMID: 25316597 DOI: 10.1517/14656566.2014.968551]
- 41 **Scheen AJ**. Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. *Clin Pharmacokinet* 2015; **54**: 691-708 [PMID: 25805666 DOI: 10.1007/s40262-015-0264-4]
- 42 **Zinman B**, Lachin JM, Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med* 2016; **374**: 1094 [PMID: 26981940 DOI: 10.1056/NEJMc1600827]
- 43 **Wanner Ch**, Inzucchi SE, Zinman B. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *N Engl J Med* 2016; **375**: 1801-1802 [PMID: 27806236 DOI: 10.1056/NEJMc1611290]
- 44 **Scheen AJ**. Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes. *Clin Pharmacokinet* 2016 Dec 30; Epub ahead of print [PMID: 28039605 DOI: 10.1007/s40262-016-0498-9]
- 45 **Filippatos TD**, Liberopoulos EN, Elisaf MS. Dapagliflozin in patients with type 2 diabetes mellitus. *Ther Adv Endocrinol Metab* 2015; **6**: 29-41 [PMID: 25678954 DOI: 10.1177/2042018814558243]
- 46 **Nyström T**, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. *Diabetes Obes Metab* 2017; **19**: 831-841 [PMID: 28116795 DOI: 10.1111/dom.12889]
- 47 **Montorio I**, Izal M. The Geriatric Depression Scale: a review of its development and utility. *Int Psychogeriatr* 1996; **8**: 103-112 [PMID: 8805091 DOI: 10.1017/S1041610296002505]

**P- Reviewer:** Bidel S, Hamasaki H, Liu SH **S- Editor:** Ji FF  
**L- Editor:** A **E- Editor:** Wu HL





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

